O2 RegenTech Receives $600,000 to Develop Oxygenating Wound Treatments

Startup provides easy-to-use solutions for chronic wound healing

Cleveland, Ohio, UNITED STATES

AKRON, Ohio, Jan. 26, 2017 (GLOBE NEWSWIRE) -- O2 RegenTech, a medical technology company focused on wound care solutions, has been awarded a $225,000 National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant to conduct research and development on its oxygenating wound dressing that enhances chronic wound healing. Additionally, the company received a $225,000 National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant and $150,000 from the Ohio Third Frontier (OTF) Technology Validation and Startup Fund (TVSF).

The three most important factors in wound healing are oxygen, moisture, and protection from bacteria to prevent infections. Currently, there are no wound treatments available that offer all three components at once, requiring patients to use a combination of different bandages, dressings, ointments, and other treatments. O2 RegenTech aims to make wound care simpler with its proprietary product, OXAID, a treatment that provides all three important components to promote wound healing in one easy-to-use dressing.

“O2 RegenTech is extremely excited to receive the support of the NSF, the NIH, and the OTF,” said Dr. Andreas Inmann, President & CEO of O2 RegenTech. “This funding validates our approach and will be instrumental in moving our technology closer to regulatory submission and commercialization.”

About O2 RegenTech
O2 RegenTech LLC is a medical technology company focused on wound care solutions. The technology is protected by pending patents licensed from The University of Akron in Akron, OH. For more information: www.o2regentech.com.

Contact Information:
Andreas Inmann, PhD, MBA
President & CEO
(267) 231-8908